For adults with a diagnosis of Major Depressive Disorder (MDD) currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of CYB003, compared to placebo, in treating symptoms of MDD in adult participants.

This study is sponsored by Cybin.

For adults with a diagnosis of Major Depressive Disorder (MDD) who continue to experience symptoms despite being on an antidepressant medication.

The goal of this study is to evaluate the efficacy, safety, and tolerability of ABX-002, an oral thyroid hormone receptor-beta (TRβ) agonist, as an adjunctive treatment for MDD. Participants will receive either ABX-002 or placebo in addition to their current antidepressant for approximately six weeks.

This study is sponsored by Autobahn Therapeutics, Inc.

This study is designed to evaluate the efficacy of a single dose of MM-120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of anxiety symptoms.

This study is sponsored by Mind Medicine, Inc.

For adults with a diagnosis of Major Depressive Disorder (MDD) who continue to experience symptoms despite being on an antidepressant medication.

The goal of this study is to evaluate the efficacy, safety, and tolerability of ABX-002, an oral thyroid hormone receptor-beta (TRβ) agonist, as an adjunctive treatment for MDD. Participants will receive either ABX-002 or placebo in addition to their current antidepressant for approximately six weeks.

This study is sponsored by Autobahn Therapeutics, Inc.

This is a phase 3 open-label study evaluating the long-term safety and tolerability of the drug NBI-1117568 in the treatment of adults with schizophrenia.

This study is sponsored by Neurocrine Biosciences, Inc.